Advertisement

Obesity Surgery

, Volume 22, Issue 4, pp 565–571 | Cite as

Intragastric Balloon in Association with Lifestyle and/or Pharmacotherapy in the Long-Term Management of Obesity

  • Maria Grazia Farina
  • Roberto Baratta
  • Angela Nigro
  • Federica Vinciguerra
  • Concetta Puglisi
  • Roberto Schembri
  • Clara Virgilio
  • Riccardo Vigneri
  • Lucia FrittittaEmail author
Clinical Research

Abstract

Background

Intragastric balloon (BioEnterics Intragastric Balloon, BIB®) or pharmacotherapy are possible options for the treatment of obese patients when traditional approaches have failed. The aim of our study was to compare in obese patients the effect on weight loss and metabolic changes of lifestyle modifications associated with either BIB or pharmacotherapy or the two treatments in sequence as a maintenance strategy for weight loss.

Methods

Fifty obese patients were recruited and randomly assigned to lifestyle modifications combined with either BIB for 6 months (n = 30) or sibutramine (pharmacotherapy group) for 1 year (n = 20). After BIB removal, patients were randomly assigned to either correct lifestyle (BIB/lifestyle) or lifestyle plus pharmacotherapy (BIB/pharmacotherapy).

Results

At 6 months, patients treated with BIB lost significantly (P < 0.05) more weight (percent of initial weight lost, %IWL = 14.5 ± 1.2; percent of excess BMI lost, %EBL = 37.7 ± 3.2) than patients who received pharmacological treatment (%IWL = 9.1 ± 1.5, %EBL = 25.3 ± 4.1). At 1 year, the weight lost was significantly (P < 0.05) greater in patients treated with either BIB/pharmacotherapy (%IWL = 15.8 ± 2.3%, %EBL = 41.3 ± 6.7%) or BIB/lifestyle (%IWL = 14.3 ± 2.7, %EBL = 34.9 ± 6.5%) in respect to pharmacotherapy group (%IWL = 8.0 ± 1.4%, %EBL = 22.1 ± 3.9%). Moreover, patients treated sequentially with BIB/lifestyle or BIB/pharmacotherapy showed a significant (P < 0.05) improvement in insulin sensitivity and triglycerides levels.

Conclusions

BIB represents an efficacious long-term obesity treatment when supplemental strategies, as lifestyle modifications or pharmacotherapy, are established for weight maintenance after its removal.

Keywords

Obesity therapy Intragastric balloon BIB Sibutramine Lifestyle intervention 

Notes

Conflict of Interest

The authors (MGF, RB, AN, FV, CP, RS, CV, RV, and LF) declare no conflict of interest with any institution or product mentioned in the manuscript.

References

  1. 1.
    Despres JP, Pascot A, Lemieux I. Risk factors associated with obesity: a metabolic perspective. Ann Endocrinol (Paris). 2000;61 Suppl 6:31–8.Google Scholar
  2. 2.
    Vigneri P, Frasca F, Sciacca L, et al. Obesity and cancer. Nutr Metab Cardiovasc Dis. 2006;16(1):1–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006;355(8):763–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160(7):898–904.Google Scholar
  5. 5.
    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S–209S.Google Scholar
  6. 6.
    Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring). 2009;17 Suppl 3:S43–8.CrossRefGoogle Scholar
  7. 7.
    Long SD, O'Brien K, MacDonald KG, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes. A longitudinal interventional study. Diabetes Care. 1994;17(5):372–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Despres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Wing RR. Use of very-low-calorie diets in the treatment of obese persons with non-insulin-dependent diabetes mellitus. J Am Diet Assoc. 1995;95(5):569–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Doldi SB, Micheletto G, Perrini MN, et al. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology. 2004;51(55):294–7.PubMedGoogle Scholar
  11. 11.
    Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, et al. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18(7):841–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71(6):927–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Dumonceau JM. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18(12):1611–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case–control study. Obes Surg. 2004;14(5):671–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Angrisani L, Lorenzo M, Borrelli V, et al. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg. 2006;16(9):1135–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Frutos MD, Morales MD, Lujan J, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes Surg. 2007;17(2):150–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14(4):539–44.PubMedCrossRefGoogle Scholar
  18. 18.
    Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients 1 year after the intragastric balloon has been removed? Obes Surg. 2005;15(6):864–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Genco A, Bruni T, Doldi SB, et al. BioEnterics intragastric balloon: the Italian experience with 2,515 patients. Obes Surg. 2005;15(8):1161–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.PubMedCrossRefGoogle Scholar
  21. 21.
    Lopez-Nava G, Rubio MA, Prados S, et al. BioEnterics intragastric balloon (BIB). Single ambulatory center Spanish experience with 714 consecutive patients treated with one or two consecutive balloons. Obes Surg. 2011;21(1):5–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19(8):1084–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Genco A, Balducci S, Bacci V, et al. Intragastric balloon or diet alone? A retrospective evaluation. Obes Surg. 2008;18(8):989–92.PubMedCrossRefGoogle Scholar
  24. 24.
    Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Ganesh R, Rao AD, Baladas HG, et al. The Bioenteric Intragastric Balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singapore Med J. 2007;48(3):227–31.PubMedGoogle Scholar
  26. 26.
    Dastis NS, Francois E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41(7):575–80.PubMedCrossRefGoogle Scholar
  27. 27.
    James WP, Caterson ID, Coutinho W, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–17.PubMedCrossRefGoogle Scholar
  28. 28.
    Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17(5):565–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462–70.PubMedCrossRefGoogle Scholar
  30. 30.
    Vetter ML, Faulconbridge LF, Webb VL, et al. Behavioral and pharmacologic therapies for obesity. Nat Rev Endocrinol. 2010;6(10):578–88.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2011

Authors and Affiliations

  • Maria Grazia Farina
    • 1
  • Roberto Baratta
    • 1
  • Angela Nigro
    • 1
  • Federica Vinciguerra
    • 1
  • Concetta Puglisi
    • 1
  • Roberto Schembri
    • 1
  • Clara Virgilio
    • 2
  • Riccardo Vigneri
    • 1
  • Lucia Frittitta
    • 1
    • 3
    Email author
  1. 1.Endocrinology Unit, Department of Clinical and Molecular BiomedicineUniversity of Catania Medical SchoolCataniaItaly
  2. 2.Gastroenterology UnitGaribaldi HospitalCataniaItaly
  3. 3.EndocrinologyUniversity of Catania, Garibaldi HospitalCataniaItaly

Personalised recommendations